Dudley D, Gagnon D, Varner M
Department of Obstetrics and Gynecology, University of Iowa College of Medicine, Iowa City.
Obstet Gynecol. 1989 Mar;73(3 Pt 1):373-8.
Although the tocolytic effect of magnesium sulfate is well known, it has generally been used for this purpose for only brief periods. In this study, we administered intravenous magnesium sulfate tocolysis, either alone or in combination with other tocolytics, to 111 women as follows: 1) 60 (54%) received the drug for 3 or fewer days (short-term group); 2) 29 (26%) received the drug for 3-10 days (intermediate group); and 3) 22 (20%) received the drug for 10 days or longer (long-term group). Side effects (ileus and/or constipation, visual blurring, headache) were more common in the intermediate and long-term groups, but no life-threatening complications were seen. The drug was discontinued because of side effects in 7% of the patients in each group. We believe our data indicate that there need be no time limit and that magnesium sulfate tocolysis may be continued as clinically indicated.
尽管硫酸镁的宫缩抑制作用广为人知,但通常仅在短时间内用于此目的。在本研究中,我们对111名女性进行了静脉注射硫酸镁宫缩抑制治疗,单独使用或与其他宫缩抑制剂联合使用,具体如下:1)60名(54%)接受该药物治疗3天或更短时间(短期组);2)29名(26%)接受该药物治疗3 - 10天(中期组);3)22名(20%)接受该药物治疗10天或更长时间(长期组)。副作用(肠梗阻和/或便秘、视物模糊、头痛)在中期组和长期组中更为常见,但未观察到危及生命的并发症。每组均有7%的患者因副作用而停药。我们认为我们的数据表明,硫酸镁宫缩抑制治疗无需设定时间限制,可根据临床指征持续使用。